Skip to main content

Durvalumab+ Gemcitabine / Cisplatin (Neoadjuvant Treatment) and Durvalumab (Adjuvant Treatment) in Patients With MIBC

Trial Status: Active

A Global Study to Determine the Efficacy and Safety of Durvalumab in Combination with Gemcitabine+Cisplatin for Neoadjuvant Treatment and Durvalumab Alone for Adjuvant Treatment in Patients with Muscle-Invasive Bladder Cancer

Inclusion Criteria

  • Inclusion: - Patient resectable muscle-invasive bladder cancer with clinical stage T2-T4aN0/1M0 with transitional and mixed transitional cell histology - Patients must be planning to undergo a radical cystectomy - Patients who have not received prior systemic chemotherapy or immunotherapy for treatment of MIBC - ECOG performance status of 0 or 1 - Must have a life expectancy of at least 12 weeks at randomization Exclusion: - Evidence of lymph node (N2-N3) or metastatic (M1) disease at time of screening. - Prior pelvic radiotherapy treatment within 2 years of randomization to study - Prior exposure to immune-mediated therapy (with exclusion of Bacillus-Calmette Guerin [BCG]), including but not limited to other anti-CTLA-4, anti-PD-1, anti PD-L1, or anti-PD-L2 antibodies. - Current or prior use of immunosuppressive medication within 14 days before the first dose of investigational product (IP). The following are exceptions to this criterion: Intranasal, inhaled, topical steroids, or local steroid injections (eg, intra articular injection); Systemic corticosteroids at physiologic doses not to exceed 10 mg/day of prednisone or its equivalent; Steroids as premedication for hypersensitivity reactions (eg, CT scan premedication) - Receipt of live attenuated vaccine within 30 days prior to the first dose of IP. - Uncontrolled intercurrent illness - Active infection including Tuberculosis, Hepatitis B, Hepatitis C, and Human Immunodeficiency


University of Alabama at Birmingham Cancer Center
Status: ACTIVE
Contact: Lakshminarayanan Nandagopal
Phone: 205-975-5715


Los Angeles
UCLA / Jonsson Comprehensive Cancer Center
Status: ACTIVE
Contact: Kim Kelly
Phone: 310-206-8309
Palo Alto
Stanford Cancer Institute Palo Alto
Status: ACTIVE


Northwestern University
Status: ACTIVE


Iowa City
University of Iowa / Holden Comprehensive Cancer Center
Status: ACTIVE


Kansas City
University of Kansas Cancer Center
Status: ACTIVE
Contact: Ashley Shores
Phone: 913-588-1897


Ann Arbor
University of Michigan Comprehensive Cancer Center
Status: ACTIVE
Wayne State University / Karmanos Cancer Institute

New York

New York
Icahn School of Medicine at Mount Sinai
Status: ACTIVE

Trial Phase Phase III

Trial Type Treatment

Lead Organization
AstraZeneca Pharmaceuticals LP

  • Primary ID D933RC00001
  • Secondary IDs NCI-2019-02524, 2018-001811-59
  • ID NCT03732677